TAAR1 and migraine disorder: Longitudinal validation and targeted interventions are essential; the Phase 3 solriamfetol trial for SWSD [NCT06568367 (130)] – a wake-promoting agent targeting TAAR-1, dopamine, and norepinephrine pathways overlapping with migraine mechanisms—may offer translational insights for SWMD due to shared circadian disruptions, but only as a hypothesis pending dedicated, migraine-specific efficacy trials.